Influence of chemotherapy on FDG uptake by human cancer xenografts in nude mice

Journal of Nuclear Medicine

Volumn 38, Issue 5, 1997, Pages 714-717

  Yoshioka, Takashi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

chemotherapy; fluorine 18 FDG; human cancer xenograft; PET

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; MITOMYCIN C;

ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SCINTISCANNING; CANCER SIZE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; STOMACH CARCINOMA; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEOXYGLUCOSE; DOXORUBICIN; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOMYCIN; NEOPLASM TRANSPLANTATION; STOMACH NEOPLASMS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030919822     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Mosmann T. Rapid colormetric assay for cellular growth and survival: application to proliferation and cytotoxity assays. J Immunol Methods 1983;65:55-63.
2. Kuzmits R, Aigiger P, Frass M, et al. Influence of cytostatics on ATP-levels of leukemic cells. Adr Exp Med Biol 1984; 165:383-388.
3. Salmon SE, Alberts DS, Durie BGM, et al. Clinical correlations of drug sensitivity in the human stem cell assay: recent results. Cancer Res 1980;74:300-305.
4. Tanigawa N, Kern DH, Hikasa Y, Morton DL. Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture. Cancer Res 1982;42:21592164.
5. Weisenthal LM, Marden JA, Dill PL, Macaluso CK. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 1983;43:749-757.
6. Hoffman RM, Connors KM, Meerson-Monosov AZ, Herrera H, Price JH. A general native-state method for determination of proliferation capacity of human normal and tumor tissues in vitro. Proc Natl Acad Sei USA 1989;86:2013-2017.
7. Povlsen CO, Jacobsen GK. Chemotherapy of a human malignant melanoma transplanted in the nude mouse. Cancer Res 1975;35:2790-2796.
8. Bogden AE, Haskell PM, Lepage DJ, Kelton DE, Cobb WR, Esber HJ. Growth of human xenografts implanted under the renal capsule of normal immunocompetent mice. Exp Cell Biol 1979;47:281- 293.
9. Reivich M. Kühl D, Wolf A, et al. The [lxF]fluorodeoxyglucose method for measurement of local cerebral glucose utilization in man. Circ Res 1979;44:127-137.
10. Gallagher BM, Flowler JS, Gutterson Nl, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-D-glucose. ,/ Nucl Med 1978:19:1154-1161.
11. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
12. Di-Chiro Ci. Positron emission tomography using ['8F]fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radial 1986;22:360-371.
13. Yonekura Y, Benua RS, Brill AB, et al. Increased accumulation of 2-deoxy-2-(F-18)Ffluoro-D-glucose in liver métastases from colon carcinoma. J Nucl Med I982;23: 1133-1137.
14. 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer. Int J Radiât Oncol Biol Phys 1990; 19:1005-1010.
15. Wahl RL. Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993:11:2101-2111.
16. Haberkorn U. Strauss LG, Dtmitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993;34:12-17.
17. Nagata Y, Yamamoto K, Hiraoka M, et al. Monitoring liver tumor therapy with [F]FDG positron emission tomography. J Comput Assist Tomogr 1990;14:370-374.
18. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994;192:79- 86.
19. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992:33:325-329.
20. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Meet 1993;34:414-419.
21. Takahashi H, Yamagichi K, Wakui A, et al. New approach to clinical evaluation of cancer chemotherapy using positron emission tomography with I8F-FDG (2-deoxy-2t'HF]fluoro-D-glucose). Sei Res Inst Tohoku Univ 1986;69:830-838.
22. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiation in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 1988;29:1521-1525.
23. Minn H, Soini I. Fluorine-18-fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15:61-66.
24. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991;32:1655-1660.
25. 18F-2-fluoro-2-deoxy-D-glucose. Eur J Nucl Med 1986;12: 325-328.
26. Higashi K, Clavo AC, Wahl RL. In vivo assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773-779.
27. Shiue CY, Salvadori PA, Wolf AP, Fowler JS, MacGregor RR. A new improved synthesis of 2-deoxy-2-[18F]fluoro-D-glucose from 'sF-labeled acetyl hypofluorite. J Nucl Med 1982;23:899-903.
28. Kondo T, Imaizumi M, Taguchi T, et al. A model for chemosensitivity determination of anticancer agents against human cancer using nude mice. Jpn Cancer Chemother 1987;14:680-686 (in Japanese).
29. Geran RI, Greenberg NH, Macdonald MM, Shumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Res 1972;3:51-61.
30. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988;61:1776-1781.
31. Yoshioka T, Takahashi H, Oikawa H, et al. Accumulation of 2-deoxy-2['8F]fluoroD-glucose in human cancer heterotransplanted in nude mice: comparison between histology and glycolytic status. J Nucl Med 1994;35:97-103.
32. Shimoyama Y, Kubota T, [noue S, et al. Antitumor activity of cisplatin and carboplatin against human tumor xenografts serially transplanted into nude mice with reference to gastric carcinomas. Jpn J Cancer Chemother 1987;14:2682-2687.
33. Kikuchi H, Asamura M, Gamoh M, Matsushita T, Wakui A, Takahashi T. An experimental study on SRCA (subrenal capsule assay)-using some immunosuppressive maneuvers. Jpn J Cancer Chemother 1988; 15:2257-2263.
34. Eder JP, Elias A, Shea TC, et al. A Phase 1-11 study of cyclophosphamide, thiotepa and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990;8:1239-1245.
35. Antman K, Ayash L, Elias A, et al. A Phase II study of high dose cyclophosphamide, thiopenta and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992:10:102-110.